Breast Cancer

+ -Text Size

What`s New in Breast Cancer Research? TOPICS

What`s new in breast cancer research and treatment?

Researchers around the world are working to find better ways to prevent, detect, and treat breast cancer, and to improve the quality of life of patients and survivors. Some of the many active areas of research include:

  • Breast cancer causes
  • Reducing breast cancer risk
  • Managing DCIS
  • New lab tests for breast cancer
  • New imaging tests for breast cancer
  • Breast cancer treatment

Causes of breast cancer

Studies continue to uncover lifestyle factors and habits, as well as inherited genes, that affect breast cancer risk. Here are a few examples:

  • Several studies are looking at the effect of exercise, weight gain or loss, and diet on risk.
  • Studies on the best use of genetic testing for BRCA1 and BRCA2 mutations continue at a rapid pace.
  • Scientists are exploring how common gene variations (small changes in genes that are not as significant as mutations) may affect breast cancer risk. Gene variants typically have only a modest effect on risk, but when taken together they may potentially have a large impact.
  • Potential causes of breast cancer in the environment have also received more attention in recent years. While much of the science on this topic is still in its earliest stages, this is an area of active research.
  • A large, long-term study funded by the National Institute of Environmental Health Sciences (NIEHS) is now being done to help find the causes of breast cancer. Known as the Sister Study, it has enrolled 50,000 women who have sisters with breast cancer. This study will follow these women for at least 10 years and collect information about genes, lifestyle, and environmental factors that may cause breast cancer. An offshoot of the Sister Study, the Two Sister Study, is designed to look at possible causes of early onset breast cancer. To find out more about these studies, call 1-877-4-SISTER (1-877-474-7837) or visit the Sister Study website (

Reducing breast cancer risk

Researchers continue to look for medicines that might help lower breast cancer risk, especially in women who are at high risk.

  • Hormone therapy drugs are typically used to help treat breast cancer, but some might also help prevent it. Two drugs, tamoxifen and raloxifene, are already approved for this purpose, although concerns about side effects have limited their use. Aromatase inhibitors such as exemestane, anastrozole, and letrozole are also being studied to reduce the risk of breast cancer.
  • Fenretinide, a drug related to vitamin A, is also being studied as a way to reduce the risk of breast cancer. In a small study, this drug reduced breast cancer risk as much as tamoxifen.
  • Other clinical trials are looking at breast cancer reduction as an unintended effect of drugs used for other reasons. Drugs currently being researched include bisphosphonates (drugs for osteoporosis), and statins (such as atorvastatin and lovastatin), which are used to lower cholesterol.
  • Dietary supplements are also being studied to see if they can reduce breast cancer risk. These have included grapeseed extract, folate, omega-3 fatty acids, and vitamins B6 and B12. Although some human studies of these supplements have been completed, very little has been published in the available medical literature to date.
  • Other supplements now being studied include hydroxytyrosol (a component in olive oil), curcumin, and omega-3 fatty acids (coupled with weight loss).

This type of research takes many years. It might be some time before meaningful results on any of these compounds are available.

Managing DCIS

In ductal carcinoma in situ (DCIS), the abnormal cells are just in the top layers of cells in the ducts within the breast and haven’t invaded any deeper. In some women, DCIS turns into invasive breast cancer, or sometimes an area of DCIS contains invasive cancer. In some women, though, the cells just stay within the ducts and never invade deeper or spread to lymph nodes or other organs. The uncertainty about how DCIS will behave can make it hard to choose the best treatments. Researchers are looking for ways to help with these challenges.

Researchers are studying the use of computers and statistical methods to estimate the odds that a woman’s DCIS will become invasive. Some of these methods are based on routinely available clinical information about the patient and her DCIS, while others also include information about changes in the genes in her tumor cells. Decision aids are another approach. They ask a woman with DCIS questions that help her decide which factors (such as survival, preventing recurrence, and side effects) she considers most important in choosing a treatment.

Another approach is to look at genes expressed by the DCIS cells using a test such as the Oncotype Dx DCIS Score. This test can be used to predict a woman’s chance of DCIS coming back or a new cancer developing in the same breast if she does not get radiation. So far, though, it hasn’t been studied well enough to predict how much someone would benefit from radiation after surgery for DCIS.

Another recent area of research and debate among breast cancer specialists is whether changing the name of DCIS to one that emphasizes that this is not an invasive cancer could help some women avoid overly aggressive treatment.

Newer lab tests

Tests for circulating tumor cells (CTCs)

Researchers have found that in many women with breast cancer, cells may break away from the tumor and enter the blood. These circulating tumor cells can be detected with sensitive lab tests. Although these tests can help predict which patients may go on to have their cancer come back, it isn’t clear that the use of these tests can help patients live longer. For women with advanced breast cancer, these tests may potentially help to tell if treatments are working.

Newer imaging tests

Newer imaging methods are now being studied for evaluating abnormalities that may be breast cancers.

Scintimammography (molecular breast imaging)

In this test, a slightly radioactive drug called a tracer is injected into a vein. The tracer attaches to breast cancer cells and is detected by a special camera.

This technique is still being studied to see if it will be useful in finding breast cancers. Some doctors believe it may be helpful in looking at suspicious areas found by regular mammograms, but its exact role is still unclear. Current research is aimed at improving the technology and evaluating its use in specific situations such as in the dense breasts of younger women. Some early studies have suggested that it may be almost as accurate as more expensive magnetic resonance imaging (MRI) scans. At this time, however, scintimammography should not be used as a replacement for screening mammograms.


Oncoplastic surgery

Breast-conserving surgery (lumpectomy or partial mastectomy) can often be used for early-stage breast cancers. But for some women, it can result in breasts of different sizes and/or shapes. If the tumor is larger, it might not even be possible, and a mastectomy might be needed instead. Some doctors are addressing this problem by combining cancer surgery and plastic surgery techniques, known as oncoplastic surgery. This typically involves reshaping the breast at the time of the initial surgery, and may mean operating on the other breast as well to make them more alike. This approach is still fairly new, and not all doctors are comfortable with it.

Targeted therapy drugs

Targeted therapies are a group of newer drugs that specifically target gene changes in cancer cells that help the cells grow or spread.

Some types of targeted therapy drugs are already being used to treat breast cancer, including:

  • Drugs that target HER2, including trastuzumab (Herceptin), pertuzumab (Perjeta), ado-trastuzumab emtansine (Kadcyla), and lapatinib (Tykerb)
  • Drugs that help hormone therapy work better, such as palbociclib (Ibrance) and everolimus (Afinitor)

Many other types of targeted therapies are now being studied for use against breast cancer, including:

PARP inhibitors: These drugs are most likely to be helpful against cancers caused by BRCA mutations, which include some breast cancers. These drugs have shown some promise in early clinical trials treating some types of breast and other cancers. Further studies are being done to determine when these drugs might be most helpful.

Anti-angiogenesis drugs: For cancers to grow, blood vessels must develop to nourish the cancer cells. This process is called angiogenesis. Looking at angiogenesis in breast cancer samples might help predict prognosis. Although one drug that blocks angiogenesis, known as bevacizumab (Avastin), turned out to not be very helpful in treating advanced breast cancer, this approach still may prove useful in breast cancer treatment. Several other anti-angiogenesis drugs are being tested in clinical trials.

Other targeted drugs: Other potential targets for new breast cancer drugs have been identified in recent years. Drugs based on these targets are now being studied, but most are still in the early stages of clinical trials.

Bone-directed treatments

If breast cancer spreads, it often goes to the bones. Some drugs can help treat the spread of cancer to the bones, and might even help prevent it.

Bisphosphonates: These drugs are used to help strengthen and reduce the risk of fractures in bones that have been weakened by metastatic breast cancer. Examples include pamidronate (Aredia) and zoledronic acid (Zometa).

Some studies have suggested that zoledronic acid may help other treatments, such as hormone therapy and chemo, work better. In one study of women being treated with chemo before surgery, tumors in the women getting zoledronic acid with chemo shrank more than those in the women treated with chemo alone.

Other studies have looked at the effect of giving zoledronic acid with other adjuvant treatments (like chemo or hormone therapy). Some studies have shown that this approach helped lower the risk of the cancer coming back, but others did not. The results of one study linked the use of these drugs with adjuvant chemo with an increased risk of breast cancer recurrence in younger women. Overall, the data does not support making bisphosphonates part of standard therapy for early-stage breast cancer.

Denosumab (Xgeva): This drug can also be used to help strengthen and reduce the risk of fractures in bones that have been weakened by metastatic breast cancer. It is being studied to see if it can help adjuvant treatments work better.

Last Medical Review: 06/01/2016
Last Revised: 09/13/2016